Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
Vanda Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Vanda Pharmaceuticals's pe ratio was 119.0× on Apr 30, 2024, against 55.8× a year earlier. Over the last 5 years it ranged from 4.6× to 119.0×, with a median of 28.6×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Apr 30, 2024 | 119.0× | +98.9 |
| 2023 | Dec 29, 2023 | 20.1× | −41.5 |
| 2022 | Dec 30, 2022 | 61.6× | +35.9 |
| 2021 | Dec 31, 2021 | 25.7× | −10.8 |
| 2020 | Dec 31, 2020 | 36.5× | +29.1 |
| 2019 | Dec 31, 2019 | 7.4× | −101.5 |
| 2018 | Dec 31, 2018 | 108.9× | +101.7 |
| 2016 | Jan 29, 2016 | 7.2× | −0.7 |
| 2015 | Dec 31, 2015 | 7.9× | −33.6 |
| 2011 | Oct 31, 2011 | 41.5× | – |
See a number that looks wrong?